HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Wade S Kingery Selected Research

1- (N- (2- methoxybenzyl)acetylamino)- 3- (1H- indol- 3- yl)- 2- (N- (2- (4- (piperidin- 1- yl)piperidin- 1- yl)acetyl)amino)propane (Lanepitant)

10/2012Preprotachykinin-A gene disruption attenuates nociceptive sensitivity after opioid administration and incision by peripheral and spinal mechanisms in mice.
7/2012Keratinocyte expression of inflammatory mediators plays a crucial role in substance P-induced acute and chronic pain.
8/2010Role of neuropeptide, cytokine, and growth factor signaling in complex regional pain syndrome.
12/2009The NALP1 inflammasome controls cytokine production and nociception in a rat fracture model of complex regional pain syndrome.
10/2009Role of substance P signaling in enhanced nociceptive sensitization and local cytokine production after incision.
3/2004Substance P signaling contributes to the vascular and nociceptive abnormalities observed in a tibial fracture rat model of complex regional pain syndrome type I.
7/2003A substance P receptor (NK1) antagonist can reverse vascular and nociceptive abnormalities in a rat model of complex regional pain syndrome type II.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Wade S Kingery Research Topics

Disease

21Complex Regional Pain Syndromes
01/2021 - 03/2009
21Hyperalgesia
01/2020 - 04/2000
18Pain (Aches)
03/2022 - 04/2006
14Edema (Dropsy)
10/2016 - 01/2002
5Tibial Fractures (Fracture, Tibial)
01/2020 - 03/2004
5Inflammation (Inflammations)
10/2018 - 04/2006
5Reflex Sympathetic Dystrophy (Reflex Sympathetic Dystrophy Syndrome)
08/2009 - 03/2004
3Hypertrophy
03/2022 - 01/2021
3Chronic Pain
07/2012 - 04/2006
2Lymphadenopathy
01/2021 - 01/2020
2Metabolic Bone Diseases (Osteopenia)
01/2021 - 08/2008
2Osteoporosis
10/2016 - 03/2004
2Bone Resorption
05/2010 - 08/2009
2Causalgia (Syndrome, Causalgia)
03/2004 - 07/2003
1Neuroinflammatory Diseases
01/2019
1Wounds and Injuries (Trauma)
01/2019
1Memory Disorders (Memory Loss)
01/2018
1Multiple Myeloma
10/2016
1Neoplasm Metastasis (Metastasis)
10/2016
1Blister (Bulla)
05/2014
1Skin Diseases (Skin Disease)
09/2013
1Neurogenic Inflammation
07/2012
1Neuralgia (Stump Neuralgia)
08/2008
1Body Weight (Weight, Body)
02/2005

Drug/Important Bio-Agent (IBA)

13Substance PIBA
01/2021 - 01/2002
12Nerve Growth Factor (NGF)IBA
10/2018 - 08/2008
11CytokinesIBA
01/2021 - 08/2008
11NeuropeptidesIBA
01/2020 - 03/2006
10Interleukin-6 (Interleukin 6)IBA
01/2021 - 10/2009
8Immunoglobulin M (IgM)IBA
03/2022 - 01/2018
7AntibodiesIBA
03/2022 - 08/2008
7Proteins (Proteins, Gene)FDA Link
01/2020 - 03/2004
71- (N- (2- methoxybenzyl)acetylamino)- 3- (1H- indol- 3- yl)- 2- (N- (2- (4- (piperidin- 1- yl)piperidin- 1- yl)acetyl)amino)propane (Lanepitant)IBA
10/2012 - 07/2003
5Calcitonin Gene-Related PeptideIBA
10/2018 - 05/2010
5InterleukinsIBA
10/2018 - 12/2010
5Neurokinin-1 Receptors (Neurokinin 1 Receptor)IBA
10/2014 - 07/2003
4Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
10/2014 - 12/2010
3AutoantibodiesIBA
03/2022 - 01/2017
3Morphine (MS Contin)FDA LinkGeneric
01/2019 - 04/2006
3Opioid Analgesics (Opioids)IBA
01/2019 - 04/2006
3Capsaicin (Zostrix)FDA Link
05/2010 - 01/2002
2AutoantigensIBA
01/2020 - 01/2017
2Brain-Derived Neurotrophic Factor (BDNF)IBA
01/2019 - 12/2015
2Tryptases (Tryptase)IBA
05/2014 - 04/2012
2Adrenergic Receptors (Adrenergic Receptor)IBA
08/2013 - 04/2000
2Interleukin-1 Receptors (Interleukin 1 Receptor)IBA
07/2011 - 12/2009
2InflammasomesIBA
07/2011 - 12/2009
2Interleukin 1 Receptor Antagonist Protein (Anakinra)FDA Link
07/2011 - 08/2009
2NF-kappa B (NF-kB)IBA
05/2010 - 08/2009
1Complement C5a (Complement 5a)IBA
01/2021
1Immunoglobulins (Immunoglobulin)IBA
01/2021
1Dimethyl FumarateIBA
01/2021
1Tacrolimus (Prograf)FDA LinkGeneric
01/2020
1preproenkephalinIBA
01/2019
1Toll-Like Receptor 4IBA
01/2019
1salicylhydroxamic acid (SHAM)IBA
01/2019
1Ascorbic Acid (Vitamin C)FDA LinkGeneric
10/2018
1Immunoglobulin G (IgG)IBA
01/2018
1Zoledronic Acid (Zometa)FDA Link
10/2016
1Diphosphonates (Bisphosphonates)IBA
10/2016
1Alendronate (Alendronate Sodium)FDA LinkGeneric
10/2016
1KetamineFDA LinkGeneric
12/2015
1Calcium-Calmodulin-Dependent Protein Kinase Type 2IBA
12/2015
1N-Methyl-D-Aspartate Receptors (NMDA Receptors)IBA
12/2015
1Interleukin-1 (Interleukin 1)IBA
10/2015
1Terbutaline (Brethaire)FDA LinkGeneric
08/2013
1Norepinephrine (Noradrenaline)FDA LinkGeneric
08/2013
1Adrenergic Agents (Adrenergic Drugs)IBA
08/2013
1Butoxamine (Butaxamine)IBA
08/2013
1Interleukin-6 Receptors (Interleukin 6 Receptor)IBA
11/2012
1Bromodeoxyuridine (BrdU)IBA
07/2012
1Biological ProductsIBA
07/2011
1Intercellular Signaling Peptides and Proteins (Growth Factors)IBA
08/2010
1Cathepsin KIBA
05/2010
1Interleukin-18 (Interleukin 18)IBA
12/2009
1interleukin-1beta-converting enzyme inhibitorIBA
12/2009
1protachykininIBA
10/2009
1Messenger RNA (mRNA)IBA
08/2009
1Pentoxifylline (Trental)FDA LinkGeneric
03/2009
1Freund's AdjuvantIBA
04/2006
1Analgesics (Analgesic Drugs)IBA
04/2006
1GlucocorticoidsIBA
03/2006

Therapy/Procedure

3Therapeutics
01/2021 - 09/2013
2Injections
07/2011 - 12/2010
2Analgesia
04/2006 - 04/2000
1Orthopedic Procedures
01/2019
1Combined Modality Therapy
10/2016
1Spinal Injections
10/2015
1Intradermal Injections
04/2000